Latest "Placebo Hepatitis Virus Infection" News Stories

16:45 EDT 28th August 2016 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 9,300+

Extremely Relevant

Hepatitis C virus uses Netrin-1 to hijack host cells

Hepatitis C virus (HCV) is a small, enveloped virus comprising an RNA genome encased in a protein capsid and surrounded by a lipid bilayer containing two glycoproteins. Acute infection can cause hepatitis but the virus usually persists as a chronic infection of the liver where it can cause inflammation and, eventually, hepatocellular carcinoma. How HCV subverts hepatocytes to turn them into virus-...

Immune responses and immunopathology in acute and chronic viral hepatitis

Comparing the immune responses to and immunopathogenesis of infection with hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) provides insight into the distinct outcomes of each type of viral hepatitis.

Counterattack of the hepatitis B virus

The hepatitis B virus (HBV), which is up to 100 times more infectious than HIV, is primarily transmitted through blood or other bodily fluids. HBV infects liver cells and chronic infection can lead to serious health problems such as cirrhosis or liver cancer. According to the World Health organization, chronic hepatitis B affects nearly 240 million people worldwide, killing almost 800,000 people a...

Risk of hepatitis B reactivation low in patients with RA treated with rituximab

Patients with rheumatoid arthritis and resolved hepatitis B virus infection who underwent treatment with rituximab did not experience reactivation of the infection, according to results of a multicenter Italian study.Researchers retrospectively studied data from 306 consecutive patients with rheumatoid arthritis (RA) who received treatment with rituximab (Rituxan, Genentech/Biogen Idec). Complete ...

Eiger licenses lambda to investigate potential therapy for hepatitis delta

Eiger BioPharmaceuticals Inc. announced it licensed pegylated interferon lambda-1a to Bristol-Myers Squibb to investigate the efficacy and safety of the drug as a therapeutic option for the treatment of hepatitis delta virus infection.Eiger plans to evaluate lambda, a type 3 interferon, as a potential monotherapy and combination regimen for individuals with chronic hepatitis delta virus (HDV) infe...

[Comment] Apportioning blame in the North American hepatitis C virus epidemic

A novel investigation into the North American spread of hepatitis C virus permits blame shifting, which the authors Jeffrey Joy and colleagues hope will increase the number of baby boomers who undergo testing.1 The medical community can now take its share of the responsibility for hepatitis C virus infection in its conversations with the 1945–65 birth cohort. Joy and colleagues offer evidence th...

Head and Neck Cancers May Be Linked to Hepatitis C

WEDNESDAY, April 13, 2016 -- Hepatitis C may increase the risk for certain types of head and neck cancers, researchers say. Hepatitis C is a serious liver infection caused by a virus. It's the most common bloodborne infection in the United States,...

Risk of liver cancer from hepatitis B persists even after clearing the virus

(Wiley) Long-term infection with hepatitis B virus (HBV) can cause liver inflammation and increase the risk of liver cancer. Researchers from the US Centers for Disease Control and Prevention, however, found that resolving HBV infection was not associated with reduced rates of liver cancer.

EMA recommends combination therapies for chronic hepatitis C virus

Two new combination therapies that have the potential to cure patients with long-term hepatitis C virus infection and rule out the need for interferon are being recommended for approval across the EU.

FDA Approves Expanded Use Of Roche Hepatitis C Virus RNA Test

Roche announced recently that it has received approval from the U.S. Food and Drug Administration (FDA) for its hepatitis C virus (HCV) quantitative RNA test to be used as an aid in the diagnosis of HCV infection for certain patient populations.

Gilead Sciences’ Epclusa gets FDA approval to treat chronic Hepatitis C virus infection

The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Epclusa to treat adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

Targeted Hepatitis B Virus Screening Effective in Addressing Infection, Liver Disease Risk

A community-based hepatitis B virus screening effort led by UC Davis researchers found that targeted outreach to Asian American populations can identify groups at high risk for infection and direct them to appropriate follow-up care to help prevent the onset of liver diseases, including cancer. Published online today in Public Health Reports, the

Alnylam announces phase 1/2 clinical trial of ALN-HBV RNA therapeutic

Alnylam Pharmaceuticals Inc. announced the initiation of its phase 1/2 clinical trial with ALN-HBV, a subcutaneously administered investigational RNA-interference therapeutic for the treatment of chronic hepatitis B virus infection. The trial will first be conducted on healthy volunteers, then in patients with chronic hepatitis B virus. It is based on encouraging pre-clinical data presented at the...

FDA approves Epclusa for treatment of chronic Hepatitis C virus infection –

The post FDA approves Epclusa for treatment of chronic Hepatitis C virus infection – appeared first on LifeSciences Healthcare.

Hepatitis Testing Day: 4 studies show increased testing rates

It is estimated that one in 30 baby boomers have hepatitis C virus infection and one in 12 Asian Americans and Pacific Islanders have hepatitis B virus infection. Still, a majority of the infected people in these at-risk populations are not aware of their infection. To raise awareness of these and other at-risk populations — including injection drug users and recipients of transfusions — the C...

Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor

Chronic hepatitis B virus infection is a leading cause of cirrhosis and liver cancer. Hepatitis B virus encodes the regulatory HBx protein whose primary role is to promote transcription of the viral genome, which persists as an extrachromosomal DNA circle in infected cells. HBx accomplishes this task by an unusual mechanism, enhancing transcription only from extrachromosomal DNA templates. Here we...

EMA recommends marketing authorisations for Epclusa and Zepatier to treat hepatitis C virus

The European Medicines Agency (EMA) has recommended the approval of marketing authorisations for two latest combination therapies against chronic (long-term) hepatitis C virus (HCV) infection in the European Union (EU).

Antiviral Therapies Give Hepatitis C Patients Similar Life Expectancy as General Population

The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology. Long-term development of cirrhosis and liver disorders, such as decompensation or hepatocellular carcinoma, after infection with hepatitis C virus

HCV prevalent among excessive alcohol drinkers, former drinkers

Individuals who are current excessive alcohol drinkers or are former drinkers are more likely to have hepatitis C virus infection and an increased risk for further liver damage vs. abstainers and nonexcessive drinkers, according to published findings. “Half of all people living with hepatitis C are not aware of their infection nor the serious medical risks they face when consuming alcohol,” Am...

NVR 3-778 safely reduces HBV DNA in chronic HBV patients

BARCELONA — In an ongoing phase 1b clinical trial, NVR 3-778, a hepatitis B virus core inhibitor, safely reduced HBV DNA levels in patients with chronic hepatitis B virus infection, according to a Late Breaker presentation at International Liver Congress.“There is no formal name for this medication, but it is a first-in-class inhibitor,” Man-Fung Yuen, MBBS, MD, PhD, chair and professor of g...

Medical News Today: Liver cancer risk lingers after hepatitis B virus cleared

A new study finds that the risk of developing liver cancer from infection with hepatitis B persists even after patients have apparently been cleared of the virus.

Tricks of Ticking time bomb Hepatitis B Virus

Hepatitis B virus (HBV) causes hepatitis B, an infectious disease that afflicts 230 million people worldwide, thereof 440 000 in Germany. Persistence of the virus in liver cells leads to progressive organ damage in the patient and contributes to a high risk of cirrhosis and liver cancer development....

Novel Test Allows for One-Step Diagnosis of HCV Infection

The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient,...

Harvoni effective for patients with HIV, acute HCV

BOSTON — Harvoni was safe and effective for the treatment of patients with HIV with acute hepatitis C virus infection, according to a Late Breaker presented at CROI 2016.“We are all familiar with this fixed dosed combination for the treatment of hepatitis C. However, there is currently no approved DAA therapy for patients with acute hepatitis C virus infection, including those with HIV coinfec...

[Personal View] Access to treatment for hepatitis C virus infection: time to put patients first

Sound health policy puts patients first. Antiviral regimens approved in 2014 revolutionised treatment of hepatitis C virus (HCV) infection. Most patients can now be cured. These new regimens, however, were priced at US$83 320–150 000 for a 3-month course. Public and private payers in the USA responded by limiting coverage to patients with advanced fibrosis or cirrhosis, keeping the drugs fro...

Quick Search

News Quicklinks